| J3245 | Injection, tildrakizumab, 1 mg | 3,200 | $110 | $352K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,440 | $50 | $70.5K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 450 | $70 | $32.6K |
| 17110 | The provider destroys benign lesions using techniques such as chemosurgery, cryosurgery, electrosurgery, or others. This code reports the destruction of one to 14 lesions other than skin tags or… | 450 | $60 | $27.7K |
| 12032 | This CPT® code is used for the intermediate repair of wounds to the scalp, axillae, trunk and/or extremities (excluding hands and feet) that are 2.6 to 7.5 cm in size. | 150 | $180 | $26K |
| 17000 | The provider destroys a premalignant lesion using techniques such as chemosurgery, cryosurgery, electrosurgery, or others. This code reports the destruction of the first or only lesion. | 600 | $30 | $17.9K |
| 11102 | The provider biopsies a single skin lesion using a tangential (side–ways) approach; he shaves off the lesion or scoops it out with a knife or curette. | 260 | $50 | $12.6K |
| J7308 | Aminolevulinic acid HCl for topical administration, 20%, single unit dosage form (354 mg) | 30 | $300 | $8.4K |
| 12052 | This CPT® code is used for the intermediate repair of wounds to the face, ears, eyelids, nose, lips and/or mucous membranes that are 2.6 to 5.0 cm in size. | 40 | $200 | $7.3K |
| 17262 | The provider destroys a malignant lesion on the trunk, arms, or legs using techniques such as chemosurgery, cryosurgery, electrosurgery, or others. The malignant lesion is 1.1 cm to 2.0 cm in… | 70 | $90 | $6.2K |